Bayer had hoped to sell a veterinary med plant in Missouri that it picked up a few years ago from Teva. But no one has come forward, so the German drugmaker will close the plant and lay off 130 people.
GlaxoSmithKline is recalling 1.7 million doses of its quadrivalent flu vaccine that were manufactured at a plant that ran into a series of manufacturing issues last year including an FDA warning letter. The company says there are questions about whether the vaccine is retaining its potency.
Sanofi's highly anticipated dengue vaccine is being manufactured in a facility in France built specifically for the product. But expansion is also going on at Sanofi Pasteur's vaccine operation in Swiftwater, PA, in preparation for a launch of the vax which may happen later this year.
POPULAR COMMENT THREADS
J&J's Janssen unit is recalling one lot of Ortho-Cept tablets because of the potential that the potency of the two active ingredients may not meet specifications, Health Canada reports.
More counterfeit Botox has made its way into the U.S. and, the FDA thinks, into physician offices. The agency is warning providers that they need to make sure they don't have any of it because it is believed to be unsafe.
The back labels of some bottles of Mucinex cold medicines may not show they contain acetaminophen and other active ingredients, leading U.K.-based Reckitt Benckiser to recall of 135 lots of the popular product in the U.S.
When the Justice Department issued its 131-count indictment against the now-defunct New England Compounding Center, it accused the compounding pharmacy of working on the scale of a drug manufacturer rather than a compounding pharmacy which is required to fill individual prescriptions. Among the evidence that may surface if the case goes to trial is that NECC ignored that requirement, filling prescriptions with names on them that included Big Baby Jesus, Silver Surfer, Filet O'Fish and Coco Puff.
A new study of U.S. drug shortages has found that antibiotics, including those used to treat highly resistant infections, have often been in persistent short supply, putting patients' health at risk and leaving open the chance some would die before hospitals could get their hands on drugs.
In a regulatory filing, Japan's Daiichi Sankyo said that its board has agreed to it selling some or all of its shares in Sun Pharmaceutical, which Reuters reports are now worth about $3.6 billion. No reason was given, the news service said, but its experience with Ranbaxy, which was recently acquired by Sun, has been nonstop issues.
From Our Sister Sites
In the leadup to Wednesday's FDA advisory committee meeting on Amgen's cancer-killing virus talimogene laherparepvec (T-Vec), the Big Biotech relied heavily on what it said were clear signs...
Sweden's Sobi, a close partner of Biogen Idec, is in the cross hairs of a buyout bid. But the biotech isn't saying yet just who's doing the bidding.